Received Feb 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLUARIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | es4h5 | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Slight fever; Extra Fluarix dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of fever in a 59-year-old female patient who received Flu Seasonal TIV Dresden (Fluarix 2025-2026 season) (batch number es4h5, expiry date 30-JUN-2026) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Concomitant products included Influenza vaccine inact split 3v (Fluarix) and Pneumococcal vaccine conj 7v (CRM197) (Prevnar). On 30-JAN-2026, the patient received the 2nd dose of Fluarix 2025-2026 season and Shingrix. On 30-JAN-2026, an unknown time after receiving Fluarix 2025-2026 season and not applicable after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Extra Fluarix dose). On an unknown date, the patient experienced fever (Verbatim: Slight fever). The outcome of the fever was unknown and the outcome of the extra dose administered was not applicable. It was unknown if the reporter considered the fever to be related to Fluarix 2025-2026 season, Fluarix Pre-Filled Syringe Device and Shingrix. It was unknown if the company considered the fever to be related to Fluarix 2025-2026 season, Fluarix Pre-Filled Syringe Device and Shingrix. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt date: 17-FEB-2026 The vaccine administration facility was the same as primary reporter. The batch number was not provided upon follow up with the reporter.